Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Mark Eisner, Executive Vice President and Chief Medical (TASE:BLWV) Officer at Vir Biotechnology (NASDAQ:VIR), sold a total of 10,382 shares of common stock in two transactions, according to a recent Form 4 filing. The sale comes as the biotech company, currently valued at $757.54 million, maintains a strong liquidity position with more cash than debt on its balance sheet, according to InvestingPro data.
On July 15, 2025, Eisner sold 6,796 shares at a price of $5.4682, for a total value of $37,161. These shares were sold to cover tax obligations related to the vesting of restricted stock units. On July 17, 2025, Eisner sold 3,586 shares at a weighted average price of $5.4738, realizing $19,629. The price for these shares ranged from $5.41 to $5.53. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2024. The transactions occurred amid a challenging period for VIR’s stock, which has declined 45.7% over the past six months.
Following these transactions, Eisner directly owns 104,618 shares of Vir Biotechnology. Investors watching VIR should note that the company is scheduled to report earnings on July 31. For deeper insights into VIR’s financial health and detailed analysis, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
In other recent news, Vir Biotechnology reported its first-quarter 2025 financial results, which showed a slight miss in earnings per share (EPS) forecasts and a significant shortfall in revenue projections. The company’s EPS was reported at -$0.88, slightly below the expected -$0.87, while revenue came in at $3.03 million, falling short of the projected $13.65 million. This revenue miss has raised concerns about Vir’s revenue-generating capabilities. Additionally, H.C. Wainwright adjusted its price target for Vir Biotechnology shares, reducing it to $15 from the previous $110, following the release of data from the Phase 2 MARCH study on chronic hepatitis B virus treatment, which did not meet the necessary thresholds for advancing to a Phase 3 trial. Despite this, the firm maintained a Buy rating, highlighting Vir’s ongoing work in other areas, particularly its chronic hepatitis delta virus treatment, which is seen as the main value driver. The ECLIPSE 1 Phase 3 trial is currently enrolling participants, and the ECLIPSE 2 trial is expected to start soon. The company also reported increased research and development expenses, reflecting its focus on advancing its Hepatitis Delta and oncology programs. Vir’s financial position remains strong, with approximately $1.02 billion in cash, providing a runway into mid-2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.